Royalty Pharma Appoints Vlad Coric, M.D. to the Company's Board of Directors

Core Insights - Royalty Pharma plc has appointed Vlad Coric, M.D. to its Board of Directors, effective immediately, enhancing its leadership team with his extensive biopharmaceutical experience [1][2]. Group 1: Appointment and Leadership - Vlad Coric is the Chairman and CEO of Biohaven, a biopharmaceutical company focused on neuroscience, immunology, and oncology [1][2]. - Pablo Legorreta, CEO of Royalty Pharma, expressed excitement about Coric's appointment, highlighting his entrepreneurial approach and leadership skills as valuable assets [2]. - Coric has notable experience in royalty funding, having completed multiple transactions with Royalty Pharma during his time at Biohaven [2]. Group 2: Achievements and Experience - Under Coric's leadership, Biohaven achieved FDA approval and launched Nurtec ODT for migraine treatment, and filed an NDA for zavegepant, the first intranasal CGRP antagonist for ultra-rapid migraine relief [2]. - Coric oversaw Biohaven's growth from its founding to its sale to Pfizer in May 2022 for approximately $13 billion [2]. - He has over 20 years of experience in drug discovery and clinical development, with expertise across various therapeutic areas including neurology, psychiatry, and oncology [3]. Group 3: Company Overview - Royalty Pharma, founded in 1996, is the largest buyer of biopharmaceutical royalties and a leading funder of innovation in the biopharmaceutical industry [4]. - The company collaborates with a range of innovators, from academic institutions to leading global pharmaceutical companies, and has a portfolio of royalties based on top-line sales of leading therapies [4]. - Royalty Pharma's portfolio includes royalties on over 35 commercial products and 15 development-stage candidates, indicating a strong position in the biopharmaceutical market [4].